In a clinical trial evaluating the combination of tofogliflozin and pioglitazone for treating hepatic steatosis in patients with fatty liver disease and T2DM, the combination therapy demonstrated superior improvements in steatosis, liver stiffness, alanine aminotransferase levels, and glycated hemoglobin compared to either monotherapy [209]. The gene discussed is GPT; the disease is fatty liver disease.